Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Deepak L. Bhatt MD, MPH, FACC, FAHA, FESC, MSCAI Advisory Board

Paul D. Thompson MD Advisory Board

See All Experts

featured

Published in Cardiology and

Journal Scan / Research · September 30, 2015

Spironolactone Versus Placebo, Bisoprolol, and Doxazosin to Determine the Optimal Treatment for Drug-Resistant Hypertension

The Lancet

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Ronald Victor MD

The Lancet

PATHWAY-2, a Randomised, Double-Blind, Crossover Trial: Spironolactone Versus Placebo, Bisoprolol, and Doxazosin to Determine the Optimal Treatment for Drug-Resistant Hypertension

Lancet 2015 Sep 20;[EPub Ahead of Print], B Williams, TM MacDonald, S Morant, DJ Webb, P Sever, G McInnes, I Ford, JK Cruickshank, MJ Caulfield, J Salsbury, I Mackenzie, S Padmanabhan, MJ Brown

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Spironolactone Versus Placebo, Bisoprolol, and Doxazosin to Determine the Optimal Treatment for Drug-Resistant Hypertension

Additional Info

PATHWAY-2, a Randomised, Double-Blind, Crossover Trial: Spironolactone Versus Placebo, Bisoprolol, and Doxazosin to Determine the Optimal Treatment for Drug-Resistant Hypertension

Further Reading

Mediterranean Diet, Neutrophil Count, and Carotid Intima-Media Thickness in Secondary Prevention

Post-MI Outcomes After First-Line Ablation in Patients With Tolerated VT and an LVEF >35%

Transesophageal 3D Echocardiographic Guidance for Pacemaker Lead Placement

Nonmodifiable Risk Factors Predict Outcomes in Brugada Syndrome

Development and Evaluation of a Comprehensive Prediction Model for Incident Coronary Heart Disease Using Genetic, Social, and Lifestyle–Psychological Factors

Long-Term Prognosis of Coronary Aneurysms

Using Electrocardiography to Assess Diastolic Function and Prognosis in Mitral Regurgitation

TAVI and FFR-Guided PCI vs Conventional Surgical Aortic Valve Replacement and CABG for Patients With Aortic Valve Stenosis and Complex or Multivessel Coronary Disease

Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination for Initial Treatment of Hypertension

Twofold More Cardiovascular Disease Events Decades Before Type 2 Diabetes Diagnosis

Machine Learning–Based Prediction of Death and Hospitalization in Patients With ICDs

Recently Updated